Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 7-UK to roll out Astra/Oxford COVID vaccine after world-first approval

Wed, 30th Dec 2020 07:08

* UK ahead of others once more with emergency approval

* Britain has ordered 100 million doses of the vaccine

* Health minister eyes route out of pandemic by spring

* Regulator advocates new timing of first and second doses

* Britain to prioritise first shots over boosters
(Adds detail)

By Alistair Smout and Paul Sandle

LONDON, Dec 30 (Reuters) - Britain on Wednesday became the
first country in the world to approve the coronavirus vaccine
developed by Oxford University and AstraZeneca, hoping
that rapid action will help it stem a record surge of infections
driven by a highly contagious form of the virus.

Prime Minister Boris Johnson’s government, which has ordered
100 million doses, had already fast-tracked approval of a
vaccine developed by Pfizer of the United States and Germany's
BioNTech, and administered hundreds of thousands of shots weeks
ahead of European Union countries and the United States.

Though cheaper and easier to distribute than rival vaccines,
the Oxford/AstraZeneca shot has been plagued with questions
about its most effective dosage ever since data published last
month showed some surprising results.

While other regulators have taken a more cautious approach,
Britain's MHRA was at pains to say it had resolved early doubts
and - unexpectedly - that it had found an 80% success rate for
the administration of two full doses, three months apart, higher
than the average that the developers themselves had found.

The government plans to take advantage by giving the first
dose to a larger number of people most at risk from COVID-19
before starting to administer the boosters. An advisory body
recommended doing the same with the Pfizer shot.

Jeremy Farrar, one of Britain's leading public health
experts, said the approval was to be celebrated, but urged
continuing scrutiny, saying:

"We will ... need to continue tracking and improving our
understanding of how long the protection lasts and whether (the
vaccines) can prevent transmission. This would be best achieved
by a randomised trial on the timing of the second dose."

INFECTIONS SOAR

Britain has already registered over 70,000 deaths from
COVID-19. On Tuesday it reported a record one-day jump of 53,135
new coronavirus infections, and it fears hospitals will soon
become overstretched in their peak winter months.

The AstraZeneca/Oxford vaccine could also be a game-changer
for global immunisation. Countries with relatively basic health
infrastructure have high hopes for a shot that, unlike Pfizer's,
can be stored and transported under normal refrigeration, rather
than supercooled to -70 degrees Celsius (-94 Fahrenheit).

India's Serum Institute of India (SII), the world's biggest
producer of vaccines, has made about 50 million doses of the
Oxford vaccine, and experts at India's drug regulator were
meeting on Wednesday to consider an emergency approval, two
sources said. Chile is also interested.

World Health Organization spokesman Tarik Jasarevic said the
latest vaccine was important for its "delivery attributes, the
potential scale and affordability".

Helen Fletcher, Professor of Immunology at the London School
of Hygiene and Tropical Medicine, hailed a "turning point" for
the pandemic, which has already killed 1.7 million people around
the world, sown chaos through the global economy and upended
normal life for billions.

"With more than 30 supply agreements and partner networks
established globally, the Oxford/AstraZeneca vaccine could slow
the pandemic and should save many lives within the next year."

EU DECISION SOON?

The EU regulator says it has not yet received full data on
the AstraZeneca shot and is unlikely to be able to approve it
next month - although Germany's top vaccine official said that a
rolling review of data meant a quick decision should be
possible.

The UK's COVID-19 vaccine chair, Wei Shen Lim, said a single
dose of Oxford/AstraZeneca's vaccine was around 70% effective
from 21 days until a second dose was given at 12 weeks.

The UK Medicines and Healthcare products Regulatory Agency
(MHRA) cleared up one doubt raised by the Oxford data, saying
that a 90% success rate for a half-dose followed by a full dose
had not stood up to analysis.

However, Munir Pirmohamed, chair of a government working
group on COVID-19 vaccines and involved in the approval, said
that, when two full doses were given three months apart,
"effectiveness was high, up to 80% ... which is the reason for
our recommendation".

A Reuters investigation detailed how the apparently more
effective dosing regime was the result of a miscalculation.

AstraZeneca Chief Executive Pascal Soriot told BBC radio
that Britain should be able to vaccinate tens of millions of
people by the end of the first quarter. The firm said it
expected the vaccine to work against the new variant.

Health Secretary Matt Hancock told Sky News that he was
"highly confident that we can get enough vulnerable people
vaccinated by the spring that we can now see our route out of
this pandemic".

(Reporting by Alistair Smout and Paul Sandle in London,
additional reporting by Pushkala Aripaka in Bengaluru, Kate
Kelland in London, John Miller in Zurich, Emilio Parodi in
Milan; editing by Guy Faulconbridge and Kevin Liffey)

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.